DBV Technologies announces up to $307M financing to advance Viaskin Peanut program

Clinical-stage biopharmaceutical company DBV Technologies (NASDAQ:DBVT) announced a financing of up to $306.9M (€284.5M), including gross proceeds of $125.5M (€116.3M) to be received upon closing and an aggregate of up to ($181.4M) (€168.2M) in gross proceeds if all the warrants are exercised.